Search
Systemic Lupus Erythematosus Clinical Trials
A listing of 44 Systemic Lupus Erythematosus clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 44
There are currently 44 active clinical trials seeking participants for Systemic Lupus Erythematosus research studies. The states with the highest number of trials for Systemic Lupus Erythematosus participants are California, Florida, Texas and New York.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Healthy Volunteer Clinical Studies
Recruiting
Find a study looking for volunteers at a study site near you! Some trials offer compensation for time and travel. Click through to learn more about study opportunities.
Conditions:
Healthy
Healthy Volunteers
Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of MK-6194 in adult participants with Systemic Lupus Erythematosus. The primary hypothesis is that at least 1 of the MK-6194 arms is superior to placebo in the primary endpoint of percentage of participants with systemic lupus erythematosus responder index (SRI-4) response at Week 28.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/19/2024
Locations: Arthritis & Osteoporosis Medical Center - La Palma ( Site 0108), La Palma, California +53 locations
Conditions: Systemic Lupus Erythematosus
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
Recruiting
The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/18/2024
Locations: Research Site, Anniston, Alabama +197 locations
Conditions: Systemic Lupus Erythematosus
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus
Recruiting
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include:
Study duration: 36 weeks
Treatment duration: 24 weeks
Visit frequency: every 2 weeks
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/17/2024
Locations: Achieve Clinical Research Site Number : 8400003, Birmingham, Alabama +59 locations
Conditions: Systemic Lupus Erythematosus
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Recruiting
Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE. Adverse events and change in the disease activity will be assessed.
Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE. This study is "double... Read More
Gender:
All
Ages:
Between 18 years and 63 years
Trial Updated:
06/14/2024
Locations: AZ Arthritis and Rheumatology /ID# 261848, Chandler, Arizona +255 locations
Conditions: Systemic Lupus Erythematosus
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases
Recruiting
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Local Institution - 0035, Aurora, Colorado +49 locations
Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/13/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +195 locations
Conditions: Systemic Lupus Erythematosus
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/13/2024
Locations: UCSD - Altman Clinical and Translational Research Institute (ACTRI), La Jolla, California +184 locations
Conditions: Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
Recruiting
This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/12/2024
Locations: Pinnacle Research Group; Llc, Central, Anniston, Alabama +103 locations
Conditions: Systemic Lupus Erythematosus
Study of Systemic Lupus Erythematosus
Recruiting
This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.
Patients 10 years of age and older with known or suspected SLE and their relatives may be eligible for this study. Patients will be evaluated with a medical history and physical examination, blood and urine tests. Other procedures may include:
Electrocardiogr... Read More
Gender:
All
Ages:
9 years and above
Trial Updated:
06/12/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland +1 locations
Conditions: Systemic Lupus Erythematosus
A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus
Recruiting
A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily for 48 weeks in approximately 180 adult participants with active Systemic Lupus Erythematosus (SLE).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/12/2024
Locations: University of Arizona College of Medicine - Tucson, Tucson, Arizona +66 locations
Conditions: Systemic Lupus Erythematosus
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +50 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
Recruiting
A subset of autoimmune diseases (ADs) in children and young adults are life-threatening and unresponsive to conventional treatments. In these patients, the delivery of high dose immunosuppressive therapy followed by autologous stem cell transplant (ASCT) offers a treatment strategy capable of purging the pathogenic, autoreactive immune system and an opportunity for "immune reset." This strategy has been used in adults across a myriad of indications with evidence for efficacy. This study proposes... Read More
Gender:
All
Ages:
Between 8 years and 25 years
Trial Updated:
06/11/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Systemic Lupus Erythematosus, Systemic Sclerosis
1 - 12 of 44